25 results on '"Romaguera, Jorge E."'
Search Results
2. The survival outcome of patients with relapsed/refractory peripheral T‐cell lymphoma‐not otherwise specified and angioimmunoblastic T‐cell lymphoma
3. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center
4. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma
5. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma
6. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas
7. 90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease
8. Double hit lymphoma: the MD Anderson Cancer Center clinical experience
9. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma
10. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
11. Usefulness of Flow Cytometric Immunophenotyping for Bone Marrow Staging in Patients With Mantle Cell Lymphoma After Therapy
12. Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: Phase 1 study with a dose-expansion cohort
13. Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma
14. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma
15. Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine
16. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine
17. Follicular dendritic cell sarcoma: A report of 14 cases and a review of the literature
18. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma
19. High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine
20. Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkinʼs Lymphoma
21. Phase II Study of Denileukin Diftitox for Relapsed/Refractory B-Cell Non-Hodgkinʼs Lymphoma
22. Non-Hodgkinʼs Lymphoma Affecting the Testis: Is It Curable with Doxorubicin-Based Therapy?
23. Real-Time 5′ → 3′ Exonuclease-Based PCR Assay for Detection of the t(11;14)(q13;q32)
24. Antibiotic Treatment of Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue: An Uncontrolled Trial
25. Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkinʼs lymphoma after failure to cytarabine/cisplatin combination
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.